A spokesperson from Beijing Strong Biotechnologies, Inc. (hereinafter referred to as BSBE) recently responded to investors' questions about chemiluminescence at the 2022 Annual Investor Exchange.
Q: The competitive landscape of the chemiluminescence market has been relatively well established, how do you see the first-mover advantage of other companies? What is the company's strategic layout for the chemiluminescence field?
A: The two technologies of luminescence and biochemistry cannot replace each other£¬but should be combined to provide services to clinical departments. Therefore, in recent years, luminescence and biochemical companies cross-supplement production lines. In recent years, the industry's R&D and registration thresholds have been reduced, so it is possible to have a better set of products in a shorter period of time at a relatively low cost. The market landscape is constantly changing dynamically, and it is still not too late to enter the market. Brands whose products can meet customer needs and continue to improve and enrich in the future will be able to occupy a dominant position in the market. Based on biochemical superior technology, BSBE will promote the development of products such as luminescence and hemagglutination to provide customers with richer products and better serve them with leading technology and cost. The way to achieve the layout of BSBE is not only through mergers and acquisitions, but also by considering partnerships. Sinopharm's demand for a richer product line for the company has further inspired the founders to pursue a better future. The company has stockpiled a large number of projects and talents in recent years and expects to keep presenting better performance in the future.
Q: What is the pace of the future launch of chemiluminescent reagents by BSBE? What types of projects are expected to be covered as a priority?
A: In terms of reagents, the company intends to proceed in three steps, the first step is time-oriented, and is expected to launch about 50 clinical trial-free projects in the second half of 2023, covering most of the tests except infectious diseases. The second step is to launch the second batch of projects in 2024 with mainly Class II licensed products. The third step is to launch Class III licensed products with longer registration time. In terms of instruments, the company will launch its own luminescence system in the second half of this year, using biochemistry as the engine to enter the market. And according to the registration rhythm of each province and city to coordinate arrangements.
Q: What is the technology platform for the instrumentation of the luminescence product line? Is it developed by the company or by external cooperation? What is the approximate speed of the machine?
A: The company's latest self-developed instruments are based on the alkaline phosphatase technology platform. The company will launch two instruments in 2023, a low-speed machine (maximum speed of 100 samples/hour) and a medium-speed machine (maximum speed of 400 samples/hour). A high-speed model is expected to be launched in 2024.
About BSBE
Beijing Strong Biotechnologies, Inc. (hereinafter referred to as BSBE) is a Chinese leading provider of in-vitro diagnostics (IVD) products and service.
BSBE was established in 2001, focusing on R&D, manufacturing and sales of IVD products which reach to international advanced level. BSBE was registered in Beijing, the capital of China with the registered capital of RMB501,787,943 and successfully listed on GEM in Shenzhen with the stock code 300406 in 2014.
As a Chinese leader in IVD filed, BSBE is engaged in developing the best IVD testing platform. And till now, BSBE has the system of clinical biochemistry testing, coagulation testing and blood typing. Due to the steady progression and rich experience in the years, BSBE has a worldwide sales and marketing network.
BSBE is focused on the R&D of IVD products and it has a high qualified R&D team. Under the guidance of the experts, BSBE has established clinical biochemistry platform of enzymatic method (including enzymatic cycling method), immunoturbidimetric method, latex immunoturbidimetric method, CEDIA method, EMIT method; Meanwhile, BSBE has very strong R&D team on liquid coagulation reagents. In 2018, BSBE launches its blood typing system using the DG Gel card technology.
BSBE is engaged to enter the market which efficiently type patients and identify donor match. BSBE is also a co-investigator and manufacturer of national reference material of CysC and it¡¯s the supporter of 863 Projects. The BSBE¡¯s R&D center is ¡°Beijing engineering laboratory for clinical biochemistry and immuno assay reagents¡±.
In order to meet the need of rapid development, BSBE establishes international advanced production environment and management procedure. BSBE is firmly committed to our mission of ¡°Quality first¡±, and provides high qualified testings covering clinical biochemistry and serology. BSBE can also provide diversified clinical diagnosis solutions to customers. Meanwhile, BSBE devotes itself to provide friendly experience of end-users and it has after-service team all over the country which can guarantee to solve the problems at the earliest time and professional technical support.
¡°Running with giants¡±. Since 2013, BSBE has signed the strategic cooperation agreement with international and domestic well-known enterprises, e.g: Abbott, Roche, Hitachi, Mindray and Weigo. Through more than 10 years of rapid development, BSBE becomes Chinese leading manufacturer and provider of IVD products, and an important player of international IVD market.
¡°Loyalty, Integrity, Passion¡± is BSBE¡¯s creed. Now, BSBE becomes the leader of Chinese IVD market, and makes best efforts to provide better products and services to the worldwide.
